Healwell AI Inc. has concluded its latest fiscal year with explosive top-line growth, achieving record revenue and its first-ever period of positive adjusted EBITDA. However, this operational milestone is juxtaposed against a widening net loss, presenting a complex financial picture for the healthcare artificial intelligence company.
Strategic Shift Yields Operational Profit
A decisive strategic pivot toward higher-margin business segments is credited for the improved operational performance. By concentrating its efforts on artificial intelligence, data science, and proprietary healthcare software solutions, Healwell AI secured three consecutive quarters of positive adjusted EBITDA by year-end. For the full fiscal year 2025, the company posted an adjusted EBITDA profit of $2.3 million, a significant reversal from an operating loss of $14.2 million in 2024.
This strategic focus is underscored by tangible commercial and clinical progress. The company’s proprietary DARWEN AI platform has now been validated in 47 peer-reviewed publications. Furthermore, in early March, Healwell AI secured a multimillion-dollar software contract with a major U.S. healthcare network.
Record Revenue Growth Contrasts with Bottom Line
The most striking figure from the annual report is the revenue surge. Healwell AI generated $103.8 million in revenue for fiscal 2025, representing a staggering 427% increase compared to the previous year.
Should investors sell immediately? Or is it worth buying Healwell AI?
Despite this operational breakthrough and record sales, the company’s IFRS net loss expanded from $24 million to $39.1 million. A slight moderation was visible in the fourth quarter, where the net loss per share narrowed to $0.02.
Market Reaction and Forward Guidance
Investors have responded positively to the company’s operational momentum. Over the past 30 trading days, Healwell AI’s share price has advanced by approximately 48%, closing at €0.57 in the most recent session.
The management team, led by CEO James Lee, is scheduled to provide further details on its future strategy and its approach to addressing the remaining net losses. The annual results will be discussed in an official conference call later today.
Ad
Healwell AI Stock: Buy or Sell?! New Healwell AI Analysis from July 22 delivers the answer:
The latest Healwell AI figures speak for themselves: Urgent action needed for Healwell AI investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 22.
Healwell AI: Buy or sell? Read more here...
